Eli Lilly vs. FDA: Inside the Fight Over Whether Retatrutide Is a Drug or a Biologic

The headline version of this story is that Eli Lilly is fighting to get a favorable drug classification, which reads like routine corporate litigation. It is not routine, and the classification question is not really about labeling. What Lilly is actually litigating is whether retatrutide can ever legally be compounded, whether it gets 12 years of market exclusivity instead of 5, and whether a ruling on one molecule ends up setting the counting standard for an entire class of peptide therapeutics sitting near the same structural line. None of that is resolved yet, and no outcome is guaranteed by the case’s current posture.

On one side is the FDA, which classified retatrutide as a conventional drug in March 2024. On the other is Lilly, which has spent nearly two years in federal court arguing that classification is wrong. The dispute has already produced one mixed ruling, an active appeal, and a September 2026 oral argument date. The sections below separate what has actually happened from what remains an open question, and set out how the case connects, and does not connect, to Canadian regulatory status.

What the Dispute Is Actually About

Under U.S. law, a “biological product” must meet specific structural criteria, including, per FDA’s interpretation, being built from more than 40 alpha amino acids in a single chain. Lilly asked the FDA to classify retatrutide as a biologic. The FDA said no, concluding the compound did not meet that threshold or qualify as sufficiently analogous to a protein under its counting rules.

Lilly disagreed and sued.

Question	Conventional drug (NDA)	Biologic (BLA)
Approval pathway	New Drug Application	Biologics License Application
Market exclusivity	5 years	12 years
Compounding eligibility	Compounding exemptions under Sections 503A/503B may apply	Not eligible for 503A/503B compounding exemptions
Medicare price negotiation timing	Eligible 7 years post-approval	Eligible on a different, generally later timeline
Governed by	Section 505 of the FD&C Act	Section 351 of the Public Health Service Act
Jurisdiction	United States	United States

Case Timeline

November 2023. Lilly first submitted a request for the FDA to designate retatrutide a biologic. The request was rejected for missing required information.

January 2024. Lilly refiled.

March 2024. The FDA issued its determination: retatrutide would be regulated as a conventional drug, not a biologic.

September 2024. Lilly filed suit against the FDA and HHS in the U.S. District Court for the Southern District of Indiana, challenging the classification.

September 30, 2025. The district court issued a mixed ruling. It upheld the FDA’s conclusion that retatrutide is not a protein outright, but set aside the agency’s separate reasoning on whether the compound is “analogous to a protein,” sending that narrower question back to the FDA.

February 2026. Lilly appealed to the Seventh Circuit, asking the appellate court to go further and order retatrutide classified as a biologic outright.

September 24, 2026. Oral arguments are scheduled at the Seventh Circuit.

Why Classification Is Worth Billions (and Why It’s About More Than Exclusivity)

The immediate financial stakes are large. A biologic license carries 12 years of U.S. market exclusivity. A conventional drug approval carries 5. For a molecule with commercial potential in the same range as Lilly’s existing obesity franchise, that seven-year gap has been estimated in the tens of billions of dollars.

But the more consequential piece of this dispute may not be exclusivity at all. Legal analysts tracking the case have pointed to compounding access as the likely core motivation. Attorney and former compounding pharmacist Mark Boesen, commenting on Lilly’s litigation strategy, said he believes closing off the compounding pathway is likely the primary driver behind the suit.

Here’s why that matters: biological products licensed under Section 351 of the Public Health Service Act are not eligible for the compounding exemptions available under Sections 503A and 503B of the FD&C Act. If retatrutide is ultimately classified as a biologic, there would be no lawful pathway for a compounding pharmacy to prepare the compound from bulk drug substance, a restriction that does not apply the same way to conventional drugs like semaglutide and tirzepatide today.

The Precedent Problem

Legal commentary on the case has flagged a broader issue sitting underneath the retatrutide-specific dispute: whatever amino-acid-counting standard the FDA is ultimately required to articulate on remand will not apply only to retatrutide. A growing number of modern peptide therapeutics sit near the same 40-amino-acid boundary, and many use branched structures, non-alpha residues, or lipid side chains that make a simple count ambiguous. Any standard that emerges from this case is likely to become the reference point for classifying that broader group of compounds, well beyond Lilly’s own portfolio.

Prerequisite Condition: Nothing Here Is Resolved Yet

As of this writing, retatrutide remains classified as a conventional drug. No court has ordered it reclassified as a biologic, and the Seventh Circuit has not yet ruled. The September 30, 2025 district court decision was a remand on one narrow question, not a final resolution, and Lilly’s appeal is asking the appellate court to go further than that remand rather than simply defending it.

Lilly has continued moving forward with development in parallel with the litigation. In its Q2 2026 earnings call, CEO David Ricks confirmed the company still intends to submit a completed Phase III data package for retatrutide in Q1 2027, regardless of how the classification dispute resolves. That submission timeline is not contingent on the litigation’s outcome, and a ruling in Lilly’s favor would not itself constitute approval of anything. It would only change which regulatory pathway governs the eventual approval decision.

[Image: federal courthouse or Seventh Circuit filing documents, representing the appellate stage of the litigation]

What This Means for Canadian Research Use

The U.S. classification fight is playing out independently of how Canada treats retatrutide. Canadian regulators have already taken a clear position, one that is not waiting on the outcome of Lilly’s litigation.

In April 2026, Health Canada issued a public advisory warning consumers against unauthorized injectable peptide products sold online. Retatrutide was named directly among the compounds identified in seized shipments, alongside other peptides such as BPC-157, CJC-1295, TB-500, and melanotan I and II. Health Canada’s position is that peptides intended for human use are generally regulated as prescription drugs in Canada, and that a “for research use only” label does not exempt a product from that requirement or make it legal to sell or use.

That advisory was not a one-off statement. In June 2026, the Superior Court of Québec granted Health Canada a permanent injunction against Canlab Research, a Quebec-based online retailer, following earlier enforcement action against the company. The injunction bars Canlab Research from manufacturing, testing, distributing, selling, or advertising unauthorized injectable peptides in Canada, including through websites and social media accessible from within the country. Health Canada has said it will continue monitoring compliance across the sector and may pursue further enforcement action.

The two regulatory tracks are also diverging in real time. In late July 2026, the FDA’s Pharmacy Compounding Advisory Committee recommended expanding compounded access to several peptide substances in the U.S. Legal analysts have been clear that this development has no bearing on Canada. Health Canada’s requirement that peptide products intended for human use be authorized before sale or marketing remains unchanged regardless of how U.S. compounding policy evolves. In other words, even a favorable outcome for Lilly at the Seventh Circuit, or a loosening of U.S. compounding rules generally, would not alter retatrutide’s current status in Canada, where it has no Drug Identification Number and has not been authorized for any human use.

Frequently Asked Questions

Q1: Has retatrutide been reclassified as a biologic?

Direct Answer: No. As of this writing, retatrutide remains classified as a conventional drug. Litigation over that classification is ongoing at the Seventh Circuit, with no final ruling issued.

• Current status: classified as a drug under an NDA pathway, not a biologic under a BLA pathway.
• What has happened so far: a mixed district court ruling and a pending appeal, not a final determination.
• What has not happened: any court order reclassifying the compound.

Q2: What would change if Lilly wins the appeal?

Direct Answer: A win would shift retatrutide toward biologic status, extending U.S. market exclusivity from 5 to 12 years and closing off the compounding exemptions currently available to conventional drugs in its class.

• Exclusivity: 12 years under a BLA versus 5 under an NDA.
• Compounding: biologics are not eligible for Section 503A/503B compounding exemptions.
• Precedent: the counting standard applied could extend to other peptide compounds near the same amino acid threshold.

Q3: Does this litigation affect whether retatrutide can be compounded right now?

Direct Answer: No. Retatrutide’s compounding status has not changed as a result of this case. It remains governed by its current conventional-drug classification while the litigation proceeds.

• No interim order has altered current compounding eligibility.
• Any change would only take effect after a final ruling, and possibly only after further FDA action on remand.
• The Q1 2027 Phase III submission timeline is proceeding independently of the litigation.

Q4: Does this case change retatrutide’s regulatory status in Canada?

Direct Answer: No. The litigation is a U.S. domestic dispute with no application in Canadian law. Health Canada’s position on retatrutide is unaffected by it.

• Health Canada named retatrutide directly in its April 2026 advisory on unauthorized injectable peptides.
• Retatrutide has no Drug Identification Number in Canada and is not authorized for any human use.
• Canadian enforcement, including a June 2026 permanent injunction against an online peptide retailer, has continued independent of U.S. developments.

Q5: When will the case be resolved?

Direct Answer: Oral arguments at the Seventh Circuit are scheduled for September 24, 2026. No timeline has been announced for a ruling after that date.

• The district court’s prior ruling was a partial remand, not a final decision.
• A Seventh Circuit ruling could affirm, reverse, or send the case back to the FDA again.
• Even a final ruling would not itself constitute drug approval or a change in compounding rules in Canada.

What to Watch Next

• The outcome of oral arguments at the Seventh Circuit on September 24, 2026.
• Whether the FDA is required to articulate a new, more precise standard for “analogous to a protein” on remand.
• Whether that standard gets applied to other peptide compounds sitting near the same structural threshold.
• Lilly’s Q1 2027 BLA/NDA submission timeline, which is proceeding independent of the litigation’s outcome.
• Whether Health Canada issues further enforcement actions against online peptide retailers following the Canlab Research injunction.
• Whether Canada’s regulatory posture on peptide products shifts at all in response to U.S. developments, or continues on its current, separate track.

---

This article covers publicly reported litigation and regulatory proceedings for informational purposes. It does not constitute legal advice, and readers with compounding, sourcing, or regulatory questions specific to their own operations should consult qualified legal counsel.

---